Efficacy and safety of OK-432 immunotherapy of lymphatic malformations

Laryngoscope

Volumn 119, Issue 1, 2009, Pages 107-115

  Smith, Mark C ^a   Zimmerman, M Bridget ^b   Burke, Diane K ^c   Bauman, Nancy M ^c   Sato, Yutaka ^c   Smith, Richard J H ^c,d  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Immunotherapy; Lymphatic malformation; Macrocystic; Microcystic; OK 432

Indexed keywords

PICIBANIL; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGED; AIRWAY OBSTRUCTION; ARTICLE; BLEEDING; BRACHIAL PLEXUS INJURY; CERVICOFACIAL LYMPHATIC MALFORMATION; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EDEMA; ERYTHEMA; FEMALE; FOLLOW UP; HEAD AND NECK MALFORMATION; HUMAN; IMMUNOTHERAPY; INFANT; INFECTION; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; PAIN; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SUBMENTAL INTRACYSTIC HEMORRHAGE; SWELLING; METHODOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; SAFETY; TREATMENT OUTCOME; UNITED STATES; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOTHERAPY; INFANT; LYMPHATIC ABNORMALITIES; MALE; MIDDLE AGED; PICIBANIL; PROSPECTIVE STUDIES; SAFETY; TREATMENT OUTCOME; UNITED STATES;

EID: 63249108062     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1002/lary.20041     Document Type: Article

References (15)

1. Bloom D., Perkins J., Manning S. Management of lymphatic malformations. Curr Opin Otolaryngol Head Neck Surg 2004; 12(6) :500-504.
2. Luzzatto C., Midrio P., Tchaprassian Z., Guglielmi M. Sclerosing treatment of lymphangiomas with OK-432. Arch Dis Child 2000; 82(4) :316-318.
3. Orford J., Barker A., Thonell S., King P., Murphy J. Bleomycin therapy for cystic hygroma. J Pediatr Surg 1995; 30(9) :1282-1287.
4. Ogita S., Tsuto T., Tokiwa K., Takahashi T. Intracystic injection of OK-432: a new sclerosing therapy for cystic hygroma in children. Br J Surg 1987; 74(8): 690-691.
5. Ogita S., Tsuto T., Nakamura K., Deguchi E., Iwai N. OK-432 therapy in 64 patients with lymphangioma. J Pediatr Surg 1994; 29(6) :784-785.
6. Ogita S., Tsuto T., Nakamura K., Deguchi E., Tokiwa K., Iwai N. OK-432 therapy for lymphangioma in children: why and how does it work? J Pediatr Surg 1996; 31(4): 477-480.
7. Fujino A., Moria Y., Morikawa Y., et al. A role of cytokines in OK-432 injection therapy for cystic lymphangioma: an approach to the mechanism. J Pediatr Surg 2003; 38(12): 1806-1809.
8. Smith R., Burke D., Sato Y., Poust R., Kimura K., Bauman N. OK-432 therapy for lymphangiomas. Arch Otolaryngol Head Neck Surg 1996; 122(11) :1195-1199.
9. Giguere C., Bauman N., Sato Y., et al. Treatment of lymphangiomas with OK-432 (Picibanil) sclerotherapy. Arch Otolaryngol Head Neck Surg 2002; 128(10) :1137-1144.
10. Grabb WC, Dingman RO, Oneal RM, Dempsey PD. Facial hamartomas in children: neurofibroma, lymphangioma, and hemangioma. Plast Reconstr Surg 1980; 66(4): 509-527.
11. de Serres L., Sie K., Richardson M. Lymphatic malformations of the head and neck: a proposal for staging. Arch Otolaryngol Head Neck Surg 1995; 121(5) :577-582.
12. Sichel J., Udassin R., Gozal D., Koplewitz B., Dano I., Eliashar R. OK-432 therapy for cervical lymphangioma. Laryngoscope 2004; 114(10) :1805-1809.
13. Emery P., Bailey C., Evans J. Cystic hygroma of the head and neck: a review of 37 cases. J Laryngol Otol 1984; 98(6) :613-619.
14. Hamoir M., Plouin-Gaudon I., Rombaux P., et al. Lymphatic malformations of the head and neck: a retrospective review and support for staging. Head Neck 2001; 23(4): 326-337.
15. Kennedy T., Whitaker, Pellitteri P., Wood E. Cystic hygroma/lymphangioma: a rational approach to management. Laryngoscope 2001; 111 (11 pt 1) :1929-1937.